OTC Calcium Channel Blocker Qualification via Mobile Health App
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for making dihydropyridine-type calcium channel blockers available over-the-counter face challenges due to inappropriate patient selection and medication use, leading to safety concerns such as incorrect self-diagnosis, drug interactions, and adverse reactions, as patients may not properly understand or follow labeling instructions.
Innovation Solution
A system and method for qualifying human subjects for over-the-counter delivery of dihydropyridine-type calcium channel blockers by conducting surveys and running results against filters to ensure safe use, including filters for contraindications and risk factors, with warnings and acknowledgments to ensure proper use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If dihydropyridine-type calcium channel blockers are made available over-the-counter, then accessibility and availability of treatment is improved, but patient safety and appropriate use deteriorates due to inability to properly self-select and self-medicate
Solution Approach 1:
A mobile health application serves as an intermediary between the patient and the medication, providing automated qualification assessment, education, and monitoring functions. The application evaluates patient responses to survey questions, determines eligibility based on pre-programmed criteria, and guides patients through the qualification process, thereby maintaining safety while enabling OTC accessibility.
Solution Approach 2:
The system enables patients to self-qualify through automated electronic surveys and assessments conducted via the mobile health application. Patients independently complete questionnaires, receive immediate feedback on their eligibility, and are guided through the qualification process without requiring physician intervention, thus improving accessibility while maintaining safety through standardized automated criteria.
2Productivity
If patients are allowed to self-medicate with dihydropyridine-type calcium channel blockers, then healthcare costs and physician workload are reduced, but incorrect self-diagnosis and inappropriate drug use increase
Solution Approach 1:
The mobile health application implements continuous feedback mechanisms where patient responses to survey questions are immediately evaluated against pre-programmed clinical criteria. The system provides real-time feedback on qualification status, educates patients about their results, and guides them through the assessment process, ensuring accurate self-diagnosis while reducing reliance on physician resources.
Solution Approach 2:
The system performs preliminary qualification assessment through automated electronic surveys before patients can access the medication. By pre-evaluating patient eligibility using standardized criteria programmed into the application, the system ensures accurate self-diagnosis and appropriate patient selection before treatment begins, preventing inappropriate drug use while maintaining healthcare efficiency.
3Reliability
If comprehensive screening and qualification processes are implemented, then patient safety is improved, but system complexity and administrative burden increase
Solution Approach 1:
The system replaces manual physician review and paper-based screening processes with automated electronic surveys and computer-based qualification algorithms. The mobile health application automatically evaluates patient responses, applies qualification criteria, and determines eligibility without requiring manual administrative processing, thereby maintaining comprehensive safety screening while reducing system complexity and administrative burden.
Data Source
AI summary
A method is provided for lowering blood pressure in a subject in need thereof by administering a dihydropyridine-type calcium channel blocker pharmaceutical composition to a subject qualified for over-the-counter access to the dihydropyridine-type calcium channel blocker pharmaceutical composition. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes isradipine, nifedipine, or nisoldipine. In some embodiments, the dihydropyridine-type calcium channel blocker pharmaceutical composition includes 3-O-ethyl 5-O-methyl 2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate or a pharmaceutically acceptable salt thereof.